AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates

分组1 - AbCellera Biologics Inc. reported a quarterly loss of $0.03 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.18, representing an earnings surprise of +83.56% [1] - The company posted revenues of $44.85 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 565.48%, compared to revenues of $5.05 million a year ago [2] - Over the last four quarters, AbCellera has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] 分组2 - The stock has underperformed, losing about 11.4% since the beginning of the year, while the S&P 500 has declined by only 0.1% [3] - The current consensus EPS estimate for the coming quarter is -$0.16 on revenues of $16.81 million, and -$0.67 on revenues of $57.07 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which AbCellera belongs, is currently in the top 37% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]